Romiplostim, Alzheimer's drugs in large group of Japanese approvals
This article was originally published in Scrip
A large group of products has received formal final approval from Japan's ministry of health, labour and welfare after a series of positive opinions over the past few months, with the new clearances including several important new therapies for rare disorders and Alzheimer's disease.
You may also be interested in...
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
In this week's podcast version of Five Must-Know Things, hear about possible new life for Tecfidera, activist investors and GSK, a new mRNA vaccine in Europe, diversity in clinical trials, and a look at last year’s drug launches.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.